Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Monoclonal Antibody
100%
Colorectal Carcinoma
100%
Detection Efficiency
100%
Technetium
100%
Radioimmunoimaging
100%
Unknown Origin
50%
Colorectal Cancer Recurrence
50%
Imaging Studies
16%
Whole-body
16%
Germany
16%
Consecutive Patients
16%
Colorectal Cancer
16%
Highly Reliable
16%
Computed Tomography
16%
Multicenter Clinical Trial
16%
Blood Levels
16%
Resection
16%
Diagnostic Work-up
16%
Patient Management
16%
Abdomen
16%
Imaging Modalities
16%
Recurrent Disease
16%
Diagnostic Procedures
16%
Pathologic
16%
Antibody Concentration
16%
Immunoglobulin G1
16%
Body Regions
16%
Single-photon Emission Computed Tomography (SPECT)
16%
Tumor-like Lesions
16%
Patient Referral
16%
Technetium-99m
16%
International Atomic Energy Agency
16%
CEA Levels
16%
Primary Colorectal Cancer
16%
Pertechnetate
16%
Marburg
16%
Nursing and Health Professions
Monoclonal Antibody
100%
Colorectal Carcinoma
100%
Recurrent Disease
100%
Technetium
100%
Carcinoembryonic Antigen
50%
Cancer Recurrence
50%
Imaging
33%
Blood Level
16%
Side Effect
16%
Malignant Neoplasm
16%
Computer Assisted Tomography
16%
Patient Referral
16%
Patient Care
16%
Technetium-99m
16%
Antibody Blood Level
16%
Single-Photon Emission Computed Tomography
16%
Besilesomab
16%
Pertechnetate
16%
Immunoglobulin G1
16%
Medicine and Dentistry
Recurrent Disease
100%
Monoclonal Antibody
100%
Colorectal Carcinoma
100%
Technetium
100%
Cancer Recurrence
50%
Carcinoembryonic Antigen
50%
Malignant Neoplasm
16%
Patient Care
16%
Patient Referral
16%
Computer Assisted Tomography
16%
Clinical Trial
16%
Side Effect
16%
Immunoglobulin G1
16%
Body Regions
16%
Single-Photon Emission Computed Tomography
16%
Technetium-99
16%
Pertechnetate
16%
Besilesomab
16%
Pharmacology, Toxicology and Pharmaceutical Science
Recurrent Disease
100%
Monoclonal Antibody
100%
Colorectal Carcinoma
100%
Technetium
100%
Cancer Recurrence
50%
Carcinoembryonic Antigen
50%
Clinical Trial
16%
Malignant Neoplasm
16%
Side Effect
16%
Immunoglobulin G1
16%
Technetium 99m
16%
Besilesomab
16%
Pertechnetate
16%
Immunology and Microbiology
Monoclonal Antibody
100%
Carcinoembryonic Antigen
100%
Blood Level
33%
Computer Assisted Tomography
33%
Antibody Blood Level
33%
Immunoglobulin G1
33%
Single Photon Emission Computed Tomography
33%
Besilesomab
33%
Body Regions
33%